DataMeds AI regains Nasdaq $2.5M stockholders' equity compliance after April delisting notice

Wellgistics Health, Inc.

Nasdaq Staff notice dated Oct. 19, 2026 confirms DataMeds AI is back in compliance with Listing Rule 5550(b)(1), which requires $2.5M minimum stockholders' equity.
The April 13, 2026 delisting notice cited stockholders' equity of $(12,447,801) at Dec. 31, 2025 and a separate failure to meet the $1.00 minimum bid price.
Bid-price compliance was regained June 9, 2026; equity cure was evidenced in Form 8-K filings on Oct. 13 and Oct. 16, 2026 showing equity above $2.5M.
Company cautions that failing to evidence compliance in its next periodic report could again subject MEDS to delisting proceedings.

Featured in Daily 8-K Digest

Selected #6 for 2026-10-20. Read digest

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.